Erye Deal To Boost Fosun’s Anti-Infective Interests
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical Group is continuing on an acquisitive streak with a plan to buy an initial 65% stake in Suzhou Erye Pharmaceutical, and may eventually fully acquire the company in a deal worth nearly $250 million in total.